Overall, the present study demonstrated that A22 could up-regulate BCL-2 expression by targeting BCL-2 promoter i-motif, which showed significant anti-apoptosis effect to offset hepatocyte impairment, inflammation, and fibrogenesis in pathological progression of NAFLD/NASH. This evidence concerns the gene BCL2 and metabolic dysfunction-associated steatotic liver disease.